Soniya Abraham, Jay Parekh, Seohyuk Lee, Humayra Afrin, Mariya Rozenblit, Kim R. M. Blenman, Rachel J. Perry, Leah M. Ferrucci, Jessica Liu, Melinda L. Irwin, Maryam Lustberg
{"title":"癌症和癌症治疗中的加速衰老：生物标志物的现状","authors":"Soniya Abraham, Jay Parekh, Seohyuk Lee, Humayra Afrin, Mariya Rozenblit, Kim R. M. Blenman, Rachel J. Perry, Leah M. Ferrucci, Jessica Liu, Melinda L. Irwin, Maryam Lustberg","doi":"10.1002/cam4.70929","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Aging in humans is a heterogeneous process influenced by both biological and chronological factors. Biological age reflects an individual's physiological reserve and functional status. Increasing evidence suggests that cancer and its therapies accelerate biological aging. Many biomarkers have been evaluated to assess the biological age of patients with cancer. These biomarkers are emerging as potential tools to predict cancer-related toxicity and an individual's functional capacity as well as to individualize treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This review summarizes the current literature on aging biomarkers in cancer patients, with a focus on markers of cellular senescence and epigenetic modification. We evaluate the existing evidence supporting their use as predictors of toxicity in patients undergoing chemotherapy and radiation therapy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Biomarkers such as interleukin-6 (IL-6), leukocyte telomere length (LTL), and DNA methylation age show potential for assessing biological age, frailty, and functional reserve. The expression of p16INK4A has demonstrated promise in predicting therapy-induced toxicity and making treating decisions. However, additional confirmatory studies are necessary to further validate these biomarkers before they can be utilized as decision aids.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Aging biomarkers hold promise for individualizing cancer therapy and predicting treatment-related toxicity. However, further studies are essential to validate their reliability and support their integration into clinical practice.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70929","citationCount":"0","resultStr":"{\"title\":\"Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers\",\"authors\":\"Soniya Abraham, Jay Parekh, Seohyuk Lee, Humayra Afrin, Mariya Rozenblit, Kim R. M. Blenman, Rachel J. Perry, Leah M. Ferrucci, Jessica Liu, Melinda L. Irwin, Maryam Lustberg\",\"doi\":\"10.1002/cam4.70929\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Aging in humans is a heterogeneous process influenced by both biological and chronological factors. Biological age reflects an individual's physiological reserve and functional status. Increasing evidence suggests that cancer and its therapies accelerate biological aging. Many biomarkers have been evaluated to assess the biological age of patients with cancer. These biomarkers are emerging as potential tools to predict cancer-related toxicity and an individual's functional capacity as well as to individualize treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This review summarizes the current literature on aging biomarkers in cancer patients, with a focus on markers of cellular senescence and epigenetic modification. We evaluate the existing evidence supporting their use as predictors of toxicity in patients undergoing chemotherapy and radiation therapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Biomarkers such as interleukin-6 (IL-6), leukocyte telomere length (LTL), and DNA methylation age show potential for assessing biological age, frailty, and functional reserve. The expression of p16INK4A has demonstrated promise in predicting therapy-induced toxicity and making treating decisions. However, additional confirmatory studies are necessary to further validate these biomarkers before they can be utilized as decision aids.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Aging biomarkers hold promise for individualizing cancer therapy and predicting treatment-related toxicity. However, further studies are essential to validate their reliability and support their integration into clinical practice.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 9\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70929\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70929\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70929","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Background
Aging in humans is a heterogeneous process influenced by both biological and chronological factors. Biological age reflects an individual's physiological reserve and functional status. Increasing evidence suggests that cancer and its therapies accelerate biological aging. Many biomarkers have been evaluated to assess the biological age of patients with cancer. These biomarkers are emerging as potential tools to predict cancer-related toxicity and an individual's functional capacity as well as to individualize treatment.
Methods
This review summarizes the current literature on aging biomarkers in cancer patients, with a focus on markers of cellular senescence and epigenetic modification. We evaluate the existing evidence supporting their use as predictors of toxicity in patients undergoing chemotherapy and radiation therapy.
Results
Biomarkers such as interleukin-6 (IL-6), leukocyte telomere length (LTL), and DNA methylation age show potential for assessing biological age, frailty, and functional reserve. The expression of p16INK4A has demonstrated promise in predicting therapy-induced toxicity and making treating decisions. However, additional confirmatory studies are necessary to further validate these biomarkers before they can be utilized as decision aids.
Conclusion
Aging biomarkers hold promise for individualizing cancer therapy and predicting treatment-related toxicity. However, further studies are essential to validate their reliability and support their integration into clinical practice.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
